X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ$0.3401
Market Cap
$58M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
372 of 924
Rank in Industry
217 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
XFOR Insider Trading Activity
XFOR Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $19,252 | 2 | 13 |
Sells | $476,096 | 13 | 87 |
Related Transactions
| Baldry Mark | Chief Commercial Officer | 2 | $19,252 | 2 | $19,747 | $-495 |
| Arbet-Engels Christophe | Chief Medical Officer | 0 | $0 | 1 | $5,284 | $-5,284 |
| Taveras Arthur | Chief Scientific Officer | 0 | $0 | 1 | $43,306 | $-43,306 |
| DiBiase Mary | Chief Operating Officer | 0 | $0 | 3 | $50,161 | $-50,161 |
| Mostafa Adam S. | Chief Financial Officer | 0 | $0 | 2 | $160,848 | $-160,848 |
| Ragan Paula | President and CEO | 0 | $0 | 4 | $196,750 | $-196,750 |
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström …
Insider Activity of X4 Pharmaceuticals, Inc.
Over the last 12 months, insiders at X4 Pharmaceuticals, Inc. have bought $19,252 and sold $476,096 worth of X4 Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at X4 Pharmaceuticals, Inc. have bought $24,563 and sold $657,354 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Baldry Mark (Chief Commercial Officer) — $19,252.
The last purchase of 13,404 shares for transaction amount of $4,598 was made by Baldry Mark (Chief Commercial Officer) on 2024‑11‑15.
List of Insider Buy and Sell Transactions, X4 Pharmaceuticals, Inc.
| 2025-01-24 | Sale | Ragan Paula | President and CEO | 76,473 0.0441% | $0.45 | $34,719 | +0.42% | |
| 2025-01-24 | Sale | DiBiase Mary | Chief Operating Officer | 22,258 0.0128% | $0.45 | $10,094 | +0.42% | |
| 2025-01-24 | Sale | Baldry Mark | Chief Commercial Officer | 29,159 0.0168% | $0.45 | $13,241 | +0.42% | |
| 2025-01-24 | Sale | Arbet-Engels Christophe | Chief Medical Officer | 11,624 0.0067% | $0.45 | $5,284 | +0.42% | |
| 2025-01-24 | Sale | Mostafa Adam S. | Chief Financial Officer | 74,773 0.0431% | $0.45 | $33,947 | +0.42% | |
| 2024-11-15 | Sale | Ragan Paula | President and CEO | 31,897 0.0186% | $0.39 | $12,583 | +21.26% | |
| 2024-11-15 | Baldry Mark | Chief Commercial Officer | 13,404 0.0068% | $0.34 | $4,598 | +21.26% | ||
| 2024-10-15 | Sale | Ragan Paula | President and CEO | 31,897 0.0161% | $0.56 | $17,926 | -9.95% | |
| 2024-10-07 | Sale | Ragan Paula | President and CEO | 239,436 0.1183% | $0.55 | $131,522 | -4.22% | |
| 2024-10-07 | Sale | DiBiase Mary | Chief Operating Officer | 67,695 0.0345% | $0.57 | $38,329 | -4.22% | |
| 2024-10-07 | Sale | Taveras Arthur | Chief Scientific Officer | 76,920 0.0389% | $0.56 | $43,306 | -4.22% | |
| 2024-10-07 | Sale | Baldry Mark | Chief Commercial Officer | 11,127 0.0059% | $0.58 | $6,506 | -4.22% | |
| 2024-10-07 | Sale | Mostafa Adam S. | Chief Financial Officer | 230,645 0.1141% | $0.55 | $126,901 | -4.22% | |
| 2024-09-09 | Sale | DiBiase Mary | Chief Operating Officer | 2,642 0.0016% | $0.66 | $1,738 | -21.04% | |
| 2024-05-17 | Baldry Mark | Chief Commercial Officer | 21,646 0.009% | $0.68 | $14,654 | -33.09% | ||
| 2024-03-11 | Sale | Ragan Paula | President and CEO | 49,678 0.0287% | $0.88 | $43,856 | -25.88% | |
| 2024-03-11 | Sale | DiBiase Mary | Chief Operating Officer | 15,409 0.0089% | $0.88 | $13,591 | -25.88% | |
| 2024-03-11 | Sale | Taveras Arthur | Chief Scientific Officer | 14,235 0.0082% | $0.88 | $12,552 | -25.88% | |
| 2024-03-11 | Sale | Mostafa Adam S. | Chief Financial Officer | 52,500 0.0304% | $0.88 | $46,347 | -25.88% | |
| 2024-02-12 | Sale | Ragan Paula | President and CEO | 21,695 0.0129% | $1.01 | $21,892 | -30.63% |
Total: 111
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Baldry Mark | Chief Commercial Officer | 94123 0.0552% | $32,011.23 | 2 | 3 | |
| Ross Michael Jay | 1868961 1.0959% | $635,633.64 | 1 | 0 | ||
| GORDON CARL L | 1868966 1.0959% | $635,635.34 | 1 | 0 | ||
| SVLSF V, LLC | 10 percent owner | 1868961 1.0959% | $635,633.64 | 1 | 0 | |
| MCGUIRE TERRANCE | 1803429 1.0574% | $613,346.20 | 1 | 0 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$2,942,496 | 100 | 17.32% | $66.91M | |
$6,787,959 | 35 | 49.84% | $60.62M | |
$459,011,221 | 33 | 33.04% | $57.94M | |
$144,247,213 | 29 | 10.15% | $64.24M | |
$2,239,226 | 28 | 3.41% | $63.36M |
XFOR Institutional Investors: Active Positions
| Increased Positions | 39 | +33.62% | 14M | +13.75% |
| Decreased Positions | 42 | -36.21% | 14M | -14.07% |
| New Positions | 15 | New | 8M | New |
| Sold Out Positions | 22 | Sold Out | 12M | Sold Out |
| Total Postitions | 113 | -2.59% | 100M | -0.32% |
XFOR Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Bain Capital Life Sciences Investors, Llc | $6,682.00 | 9.89% | 16.92M | 0 | 0% | 2024-12-31 |
| Nea Management Company, Llc | $5,920.00 | 8.76% | 14.99M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $4,369.00 | 6.47% | 11.06M | -150,026 | -1.34% | 2024-12-31 |
| Vanguard Group Inc | $3,239.00 | 4.8% | 8.2M | -239,827 | -2.84% | 2024-12-31 |
| Acorn Capital Advisors, Llc | $2,888.00 | 4.28% | 7.31M | +7M | New | 2024-12-31 |
| Orbimed Advisors Llc | $2,818.00 | 4.17% | 7.13M | 0 | 0% | 2024-12-31 |
| Kingdon Capital Management, L.L.C. | $1,950.00 | 2.89% | 4.94M | +298,317 | +6.43% | 2024-12-31 |
| Geode Capital Management, Llc | $1,381.00 | 2.05% | 3.5M | +49,700 | +1.44% | 2024-12-31 |
| Axa S.A. | $1,213.00 | 1.8% | 3.07M | -4,798 | -0.16% | 2024-12-31 |
| State Street Corp | $1,208.00 | 1.79% | 3.06M | +104,402 | +3.54% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.